《如何处理信号？当前基于RET基因分型选择激酶抑制剂治疗甲状腺髓样癌的依据》勘误

Corrigendum to "How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer".

作者信息

Prazeres Hugo, Torres Joana, Rodrigues Fernando, Couto Joana P, Vinagre João, Sobrinho-Simões Manuel, Soares Paula

机构信息

Cancer Biology Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal; Molecular Pathology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98, 3000-075 Coimbra, Portugal; Department of Pathology, Faculty of Medicine of Porto University, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.

Cancer Biology Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal.

出版信息

J Thyroid Res. 2016;2016:2168046. doi: 10.1155/2016/2168046. Epub 2016 Jun 28.

DOI:10.1155/2016/2168046

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4940563/

Abstract

[This corrects the article DOI: 10.4061/2011/678357.].

摘要

[本文更正了文章的数字对象标识符：10.4061/2011/678357。]

相似文献

1

Corrigendum to "How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer".《如何处理信号？当前基于RET基因分型选择激酶抑制剂治疗甲状腺髓样癌的依据》勘误

J Thyroid Res. 2016;2016:2168046. doi: 10.1155/2016/2168046. Epub 2016 Jun 28.

2

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.MEN2A 衍生的 RET 在甲状腺髓样癌维持和增殖中的作用。

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9. doi: 10.1093/jnci/djh226.

3

[The RET gene and medullary thyroid cancer: from mutations to the planning of therapy].[RET基因与甲状腺髓样癌：从突变到治疗规划]

Chir Ital. 2009 Sep-Dec;61(5-6):531-8.

4

In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.甲状腺髓样癌中RET变异体的计算机模拟分析：从计算机到床边

Otolaryngol Head Neck Surg. 2015 Apr;152(4):650-4. doi: 10.1177/0194599815569709. Epub 2015 Mar 2.

5

Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.伴有非半胱氨酸RET突变的家族性甲状腺髓样癌：大量患者的表型-基因型关系

J Clin Endocrinol Metab. 2001 Aug;86(8):3746-53. doi: 10.1210/jcem.86.8.7767.

6

Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.RET 原癌基因突变的多样性及其在甲状腺髓样癌中的致癌机制。

Crit Rev Clin Lab Sci. 2016 Aug;53(4):217-27. doi: 10.3109/10408363.2015.1129529. Epub 2016 Jan 27.

7

A primer on the genetics of medullary thyroid cancer.《甲状腺髓样癌遗传学概论》。

Curr Oncol. 2019 Dec;26(6):389-394. doi: 10.3747/co.26.5553. Epub 2019 Dec 1.

8

Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.多代家族性甲状腺髓样癌（FMTC）：FMTC表型模拟的证据及其与甲状腺乳头状癌的关联

Clin Endocrinol (Oxf). 2002 Jan;56(1):53-63. doi: 10.1046/j.0300-0664.2001.01434.x.

9

Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.甲状腺髓样癌的分子机制：当前的诊断和治疗方法

Histol Histopathol. 2008 Jan;23(1):109-16. doi: 10.14670/HH-23.109.

10

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.酪氨酸激酶抑制剂用于治疗甲状腺髓样癌

Recent Results Cancer Res. 2015;204:227-49. doi: 10.1007/978-3-319-22542-5_11.

本文引用的文献

1

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.如何处理信号？当前以RET基因分型为导向选择激酶抑制剂治疗甲状腺髓样癌的依据。

J Thyroid Res. 2011;2011:678357. doi: 10.4061/2011/678357. Epub 2011 Jun 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。